The Journal of Clinical Pathways (11/10, Tumolo) reports researchers found “quality-adjusted progression-free survival (PFS) and time without symptoms or toxicity in women with recurrent ovarian cancer were longer with rucaparib compared with placebo.” The findings were published in the Journal of Clinical Oncology. […]
The ASCO Post (11/4) reports “researchers conducted genetic testing in more than 3,000 patients who were diagnosed with cancer,” and “found that one in eight patients with cancer had an inherited cancer-related gene mutation–and that these mutations would not have been detected in half of these patients if testing had been conducted using a standard guideline-based approach.” […]
Medscape (10/30, Osterweil, Subscription Publication) reported, “Up to 40% of patients with cancer who are treated with bevacizumab develop severe hypertension and renal toxicity,” but researchers have developed a “genetic test performed before treatment” that “could identify patients at highest risk for this potentially life-threatening complication.” The findings were presented “in a plenary session during the […]